trb chemedica develops injectable pharmaceutical products in vouvry

trb chemedica vouvry sa forms the swiss industrial core of the international trb chemedica group, which specializes in the development and manufacture of innovative pharmaceutical products for the treatment of conditions in rheumatology, ophthalmology, and neurology. the vouvry site stands out for its unique expertise in two highly specialized production areas: ganglioside extraction and the manufacture of hyaluronic acid–based injectable products. 

two complementary production units

the vouvry industrial site is organized around two distinct production units, each dedicated to a specific technology. the first unit focuses on the extraction and purification of gangliosides—complex molecules naturally present in nervous tissue that play a crucial role in the functioning of the nervous system. this specialization makes trb chemedica one of the few companies worldwide to master this delicate technology. 

the second production unit is dedicated to the manufacture of injectable products based on hyaluronic acid, a substance naturally found in the human body and widely used in medicine for the treatment of joint disorders. this production meets the strictest standards for injectable pharmaceutical products. 

an integrated r&d department

one of the major strengths of the vouvry site lies in its integrated research and development unit, which works in close collaboration with the production division. this proximity between research teams and industrial operations greatly facilitates technology transfer and process optimization. 

the vouvry site is also part of the global strategy of the trb chemedica group, which operates in many countries around the world. this international dimension gives the valais site access to global markets and the opportunity to collaborate with other centers of expertise within the group.